Louisiana State Employees Retirement System Purchases Shares of 16,700 Integer Holdings Co. (NYSE:ITGR)

Louisiana State Employees Retirement System purchased a new stake in Integer Holdings Co. (NYSE:ITGR) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 16,700 shares of the medical equipment provider’s stock, valued at approximately $1,655,000. Louisiana State Employees Retirement System owned about 0.05% of Integer as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Covestor Ltd lifted its holdings in shares of Integer by 420.6% during the 1st quarter. Covestor Ltd now owns 328 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 265 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Integer by 483.3% during the 4th quarter. Blue Trust Inc. now owns 455 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 377 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Integer by 28.5% during the 1st quarter. Tower Research Capital LLC TRC now owns 775 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 172 shares in the last quarter. State of Wyoming lifted its holdings in shares of Integer by 129.5% during the 4th quarter. State of Wyoming now owns 840 shares of the medical equipment provider’s stock valued at $58,000 after acquiring an additional 474 shares in the last quarter. Finally, Point72 Middle East FZE acquired a new position in shares of Integer during the 4th quarter valued at $96,000. Institutional investors and hedge funds own 99.29% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Bank of America upgraded shares of Integer from a “neutral” rating to a “buy” rating and lifted their target price for the company from $105.00 to $135.00 in a report on Monday, April 15th. Benchmark lifted their price target on shares of Integer from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, March 28th. KeyCorp lifted their price target on shares of Integer from $123.00 to $139.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 9th. Finally, CL King initiated coverage on shares of Integer in a research note on Thursday, March 14th. They set a “buy” rating and a $137.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $120.50.

Integer Stock Performance

Integer stock opened at $116.58 on Friday. The firm’s fifty day moving average price is $111.82 and its 200 day moving average price is $98.49. The company has a market capitalization of $3.91 billion, a price-to-earnings ratio of 43.34, a price-to-earnings-growth ratio of 1.64 and a beta of 1.10. Integer Holdings Co. has a 12-month low of $69.40 and a 12-month high of $121.53. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.80 and a quick ratio of 1.71.

Integer (NYSE:ITGR) last issued its earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.05. The business had revenue of $413.15 million for the quarter, compared to analyst estimates of $409.04 million. Integer had a net margin of 5.68% and a return on equity of 10.80%. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.11 EPS. On average, research analysts forecast that Integer Holdings Co. will post 5.3 EPS for the current fiscal year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.